代谢功能障碍相关性脂肪肝与动脉粥样硬化性心血管疾病之间的关系。

Wen Wen, Hua Fan, Shenghui Zhang, Siqi Hu, Chen Chen, Jiake Tang, Yao You, Chunyi Wang, Jie Li, Lin Luo, Yongran Cheng, Mengyun Zhou, Xuezhi Zhao, Tao Tan, Fangfang Xu, Xinyan Fu, Juan Chen, Peng Dong, Xingwei Zhang, Mingwei Wang, Yan Feng
{"title":"代谢功能障碍相关性脂肪肝与动脉粥样硬化性心血管疾病之间的关系。","authors":"Wen Wen, Hua Fan, Shenghui Zhang, Siqi Hu, Chen Chen, Jiake Tang, Yao You, Chunyi Wang, Jie Li, Lin Luo, Yongran Cheng, Mengyun Zhou, Xuezhi Zhao, Tao Tan, Fangfang Xu, Xinyan Fu, Juan Chen, Peng Dong, Xingwei Zhang, Mingwei Wang, Yan Feng","doi":"10.1016/j.amjms.2024.06.022","DOIUrl":null,"url":null,"abstract":"<p><p>Non-alcoholic fatty liver disease (NAFLD) is closely related to metabolic syndrome and remains a major global health burden. The increased prevalence of obesity and type 2 diabetes mellitus (T2DM) worldwide has contributed to the rising incidence of NAFLD. It is widely believed that atherosclerotic cardiovascular disease (ASCVD) is associated with NAFLD. In the past decade, the clinical implications of NAFLD have gone beyond liver-related morbidity and mortality, with a majority of patient deaths attributed to malignancy, coronary heart disease (CHD), and other cardiovascular (CVD) complications. To better define fatty liver disease associated with metabolic disorders, experts proposed a new term in 2020 - metabolic dysfunction associated with fatty liver disease (MAFLD). Along with this new designation, updated diagnostic criteria were introduced, resulting in some differentiation between NAFLD and MAFLD patient populations, although there is overlap. The aim of this review is to explore the relationship between MAFLD and ASCVD based on the new definitions and diagnostic criteria, while briefly discussing potential mechanisms underlying cardiovascular disease in patients with MAFLD.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Associations between metabolic dysfunction-associated fatty liver disease and atherosclerotic cardiovascular disease.\",\"authors\":\"Wen Wen, Hua Fan, Shenghui Zhang, Siqi Hu, Chen Chen, Jiake Tang, Yao You, Chunyi Wang, Jie Li, Lin Luo, Yongran Cheng, Mengyun Zhou, Xuezhi Zhao, Tao Tan, Fangfang Xu, Xinyan Fu, Juan Chen, Peng Dong, Xingwei Zhang, Mingwei Wang, Yan Feng\",\"doi\":\"10.1016/j.amjms.2024.06.022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Non-alcoholic fatty liver disease (NAFLD) is closely related to metabolic syndrome and remains a major global health burden. The increased prevalence of obesity and type 2 diabetes mellitus (T2DM) worldwide has contributed to the rising incidence of NAFLD. It is widely believed that atherosclerotic cardiovascular disease (ASCVD) is associated with NAFLD. In the past decade, the clinical implications of NAFLD have gone beyond liver-related morbidity and mortality, with a majority of patient deaths attributed to malignancy, coronary heart disease (CHD), and other cardiovascular (CVD) complications. To better define fatty liver disease associated with metabolic disorders, experts proposed a new term in 2020 - metabolic dysfunction associated with fatty liver disease (MAFLD). Along with this new designation, updated diagnostic criteria were introduced, resulting in some differentiation between NAFLD and MAFLD patient populations, although there is overlap. The aim of this review is to explore the relationship between MAFLD and ASCVD based on the new definitions and diagnostic criteria, while briefly discussing potential mechanisms underlying cardiovascular disease in patients with MAFLD.</p>\",\"PeriodicalId\":94223,\"journal\":{\"name\":\"The American journal of the medical sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The American journal of the medical sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.amjms.2024.06.022\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American journal of the medical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.amjms.2024.06.022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

非酒精性脂肪肝(NAFLD)与代谢综合征密切相关,仍然是全球主要的健康负担。全球肥胖症和 2 型糖尿病(T2DM)发病率的增加导致了非酒精性脂肪肝发病率的上升。人们普遍认为,动脉粥样硬化性心血管疾病(ASCVD)与非酒精性脂肪肝有关。在过去十年中,非酒精性脂肪肝的临床影响已超出了与肝脏相关的发病率和死亡率,大多数患者的死亡归因于恶性肿瘤、冠心病(CHD)和其他心血管疾病(CVD)并发症。为了更好地定义与代谢紊乱相关的脂肪肝,专家们在 2020 年提出了一个新术语--与脂肪肝相关的代谢功能障碍(MAFLD)。随着这一新名称的提出,诊断标准也随之更新,从而在一定程度上区分了非酒精性脂肪肝(NAFLD)和伴有脂肪肝的代谢功能障碍(MAFLD)患者群体,尽管两者之间存在重叠。本综述旨在根据新的定义和诊断标准探讨MAFLD与ASCVD之间的关系,同时简要讨论MAFLD患者心血管疾病的潜在机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Associations between metabolic dysfunction-associated fatty liver disease and atherosclerotic cardiovascular disease.

Non-alcoholic fatty liver disease (NAFLD) is closely related to metabolic syndrome and remains a major global health burden. The increased prevalence of obesity and type 2 diabetes mellitus (T2DM) worldwide has contributed to the rising incidence of NAFLD. It is widely believed that atherosclerotic cardiovascular disease (ASCVD) is associated with NAFLD. In the past decade, the clinical implications of NAFLD have gone beyond liver-related morbidity and mortality, with a majority of patient deaths attributed to malignancy, coronary heart disease (CHD), and other cardiovascular (CVD) complications. To better define fatty liver disease associated with metabolic disorders, experts proposed a new term in 2020 - metabolic dysfunction associated with fatty liver disease (MAFLD). Along with this new designation, updated diagnostic criteria were introduced, resulting in some differentiation between NAFLD and MAFLD patient populations, although there is overlap. The aim of this review is to explore the relationship between MAFLD and ASCVD based on the new definitions and diagnostic criteria, while briefly discussing potential mechanisms underlying cardiovascular disease in patients with MAFLD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信